spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising
David Hirsh 

Editorial 
Emma Naks


View the
digital version
of EBR


ebr
 
 
Featured in this issue
REGIONAL UPDATES
Regional Development: Russia

Home Advantage


In a bid to reverse its reliance on imported pharmaceutical products, Russia is boosting the domestic development and manufacturing of innovative drugs through homegrown start-ups and investment. Maria Bomer from Bomer Pharma Consultancy explains.
BioResearch and Innovation
Cell-Based Therapies

Back to the Future


They may be an emerging niche within biopharma, but cell-based therapies are enjoying a steep growth trajectory. R Lee Buckler at Cell Therapy Group, and BioCision’s Rolf Ehrhardt and Maria Thompson outline the new technologies in this area.
  BUSINESS STRATEGY
Bioclusters

Group Dynamics


Many small and medium enterprises in the biopharma space are working in clusters to exploit the benefits of a supportive business ecosystem. CEBR’s Claire Skentelbery, Fabrizio Conicella at Bioindustry Park Silvano Fumero and BioWin’s Frédéric Druck report.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

Banner of Samedan app.EBR on Samedan
Banner of SKGF.EBR on Samedan
 
Industry Events

2014 Biotech China

14-16 May 2014,

Jointly organized by Nanjing Pushlong Business Management Co., Ltd. and more than 10 national associations, The All China Biotech Conference & Exhibition (Biotech China) will be grandly held in Nanjing on May 14 - 16, 2014, creating a platform for business and academic exchanges.
More info >>

 
News and Press Releases

Steve McCairns joins expanding PCI team as UK Director of Operations

Powys, Wales – March 17, 2014 - Packaging Coordinators, Inc. (PCI) is pleased to welcome Steve McCairns as Director of Operations for its UK business.
More info >>

air transport logo

 

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement